Gyre Therapeutics Statistics
Gyre Therapeutics (L9S) Stock Statistics & Valuation Metrics
Total Valuation
Gyre Therapeutics has a market cap or net worth of EUR 436.76M. The enterprise value is EUR 770.28M.
- Market Cap
- EUR 436.76M
- Enterprise Value
- EUR 770.28M
Share Statistics
Gyre Therapeutics has 115,321,014 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 115,321,014
- Owned by Insiders
- 63.46%
- Owned by Institutions
- 3.82%
Financial Efficiency
Gyre Therapeutics’s return on equity (ROE) is 0.05 and return on invested capital (ROIC) is 5.30%.
- Return on Equity (ROE)
- 0.05
- Return on Assets (ROA)
- 0.03
- Return on Invested Capital (ROIC)
- 5.30%
- Return on Capital Employed (ROCE)
- 0.08
- Revenue Per Employee
- 186.54K
- Profits Per Employee
- 8,043.2
- Employee Count
- 625
- Asset Turnover
- 0.70
- Inventory Turnover
- 0.53
Valuation Ratios
The current PE Ratio of Gyre Therapeutics is -15.17. Gyre Therapeutics’s PEG ratio is 0.16.
- PE Ratio
- -15.17
- PS Ratio
- 3.68
- PB Ratio
- 4.17
- Price to FCF
- -18.15
- Price to Operating Cash Flow
- -19.42
- PEG Ratio
- 0.16
Income Statement
In the last 12 months, Gyre Therapeutics had revenue of 116.59M and earned 5.03M in profits. Earnings per share was 0.06.
- Revenue
- 116.59M
- Gross Profit
- 111.17M
- Operating Income
- 11.49M
- Pretax Income
- 14.44M
- Net Income
- 5.03M
- EBITDA
- 16.92M
- Earnings Per Share (EPS)
- 0.06
Cash Flow
In the last 12 months, operating cash flow was -23.16M and capital expenditures -2.59M, giving a free cash flow of -25.74M billion.
- Operating Cash Flow
- -23.16M
- Free Cash Flow
- -25.74M
- Free Cash Flow per Share
- -0.23
Dividends & Yields
Gyre Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -5.37%
- Earnings Yield
- -5.42%
Stock Price Statistics
- Beta
- 0.91
- 52-Week Price Change
- -38.51%
- 50-Day Moving Average
- 5.74
- 200-Day Moving Average
- 5.93
- Relative Strength Index (RSI)
- 37.56
- Average Volume (3m)
- 92
Important Dates
Gyre Therapeutics upcoming earnings date is Mar 30, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 30, 2027
- Ex-Dividend Date
- ―
Financial Position
Gyre Therapeutics as a current ratio of 5.60, with Debt / Equity ratio of 0.89%
- Current Ratio
- 5.60
- Quick Ratio
- 5.04
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -2.14
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Gyre Therapeutics has paid 4.56M in taxes.
- Income Tax
- 4.56M
- Effective Tax Rate
- 0.32
Enterprise Valuation
Gyre Therapeutics EV to EBITDA ratio is -18.81, with an EV/FCF ratio of -17.05.
- EV to Sales
- 3.46
- EV to EBITDA
- -18.81
- EV to Free Cash Flow
- -17.05
- EV to Operating Cash Flow
- -18.21
Balance Sheet
Gyre Therapeutics has EUR 70.04M in cash and marketable securities with EUR 3.01M in debt, giving a net cash position of EUR 67.03M billion.
- Cash & Marketable Securities
- EUR 70.04M
- Total Debt
- EUR 3.01M
- Net Cash
- EUR 67.03M
- Net Cash Per Share
- EUR 0.58
- Tangible Book Value Per Share
- EUR 1.52
Margins
Gross margin is 94.15%, with operating margin of -20.63%, and net profit margin of -20.53%.
- Gross Margin
- 94.15%
- Operating Margin
- -20.63%
- Pretax Margin
- -20.93%
- Net Profit Margin
- -20.53%
- EBITDA Margin
- -18.40%
- EBIT Margin
- -19.50%
Analyst Forecast
The average price target for Gyre Therapeutics is EUR 16.12, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 16.12
- Price Target Upside
- 291.17% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- 8.26%
- EPS Growth Forecast
- -443.88%
Scores
- Smart Score
- 4
- AI Score
- ―
